Eyepoint Pharmaceuticals’ (EYPT) Sector Perform Rating Reiterated at Royal Bank Of Canada

Eyepoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “sector perform” rating reaffirmed by investment analysts at Royal Bank Of Canada in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $5.00 target price on the stock, down from their previous target price of $37.00. Royal Bank Of Canada’s target price points to a potential upside of 2.67% from the stock’s previous close.

A number of other equities research analysts have also recently commented on the company. Jefferies Financial Group decreased their price objective on Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating for the company in a research note on Monday. Chardan Capital restated a “buy” rating and set a $65.00 target price on shares of Eyepoint Pharmaceuticals in a report on Monday. JPMorgan Chase & Co. restated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Monday. Stifel Nicolaus began coverage on shares of Eyepoint Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, HC Wainwright reiterated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Eyepoint Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $36.78.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ EYPT opened at $4.87 on Tuesday. Eyepoint Pharmaceuticals has a fifty-two week low of $3.95 and a fifty-two week high of $19.11. The firm has a market capitalization of $419.84 million, a P/E ratio of -1.30 and a beta of 1.76. The company’s 50 day simple moving average is $13.10 and its 200 day simple moving average is $13.62.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The business had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. Sell-side analysts expect that Eyepoint Pharmaceuticals will post -3.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System raised its position in shares of Eyepoint Pharmaceuticals by 2,158.3% during the first quarter. California State Teachers Retirement System now owns 105,101 shares of the company’s stock worth $1,355,000 after purchasing an additional 100,447 shares during the period. Commodore Capital LP acquired a new position in shares of Eyepoint Pharmaceuticals in the 1st quarter valued at approximately $36,414,000. Simplify Asset Management Inc. grew its position in shares of Eyepoint Pharmaceuticals by 314.9% in the 4th quarter. Simplify Asset Management Inc. now owns 375,264 shares of the company’s stock valued at $6,856,000 after purchasing an additional 284,824 shares during the period. Walleye Capital LLC bought a new stake in Eyepoint Pharmaceuticals during the 1st quarter worth approximately $3,869,000. Finally, Stempoint Capital LP increased its stake in Eyepoint Pharmaceuticals by 129.1% during the 1st quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock worth $10,451,000 after purchasing an additional 456,915 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors.

Trending Headlines about Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint said DURAVYU was non-inferior to on-label aflibercept in an ad hoc analysis that excluded an asymmetric cohort of nine patients whose vision loss was considered unrelated to wet AMD. The trial also showed a 42% reduction in treatment burden, strong anatomic control through Week 56, supplement-free treatment rates and a favorable redosing safety profile. EyePoint Announces Topline Data from LUGANO
• Positive Sentiment: Jefferies lowered its price target to $8 but maintained a “buy” rating, while Chardan reaffirmed its “buy” rating and $65 target. These bullish views indicate some analysts believe the LUGANO result may be addressable and that DURAVYU’s longer-duration treatment profile retains value.
• Neutral Sentiment: Trading in EYPT was temporarily halted for pending news before the trial results were released, reflecting the material importance of the announcement. JPMorgan reaffirmed its “neutral” rating.
• Negative Sentiment: The full trial dataset did not meet the primary endpoint because the unusual vision-loss cohort affected the result. Investors now face greater regulatory and clinical uncertainty, particularly while awaiting the second pivotal Phase 3 trial. EyePoint’s eye drug misses main goal in late-stage trial
• Negative Sentiment: Cantor Fitzgerald downgraded EyePoint from “overweight” to “neutral.” The setback prompted speculation that competing ophthalmology companies, including Ocular Therapeutix and Forma Therapeutics, may now appear more attractive, further pressuring EYPT’s valuation.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.